Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant.

about

Malignant intertrigo: A subset of toxic erythema of chemotherapy requiring recognition.

P2860

Q30275218-E8ED0D55-9D76-4460-BAD3-E1B97853C88F

P2860

Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant.

Item

http://www.wikidata.org/entity/Q44801887

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Toxic erythema of chemotherapy ...... or allogeneic PBSC transplant.

@en

Toxic erythema of chemotherapy ...... or allogeneic PBSC transplant.

@nl

type

Item

label

Toxic erythema of chemotherapy ...... or allogeneic PBSC transplant.

@en

Toxic erythema of chemotherapy ...... or allogeneic PBSC transplant.

@nl

prefLabel

Toxic erythema of chemotherapy ...... or allogeneic PBSC transplant.

@en

Toxic erythema of chemotherapy ...... or allogeneic PBSC transplant.

@nl

P1476

Toxic erythema of chemotherapy ...... or allogeneic PBSC transplant.

@en

P2093

D L Cooper

http://www.w3.org/2001/XMLSchema#string

J L Bolognia

http://www.w3.org/2001/XMLSchema#string

S E Seropian

http://www.w3.org/2001/XMLSchema#string

T L Parker

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia.

Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome.

Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide

Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.

The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia.

Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation.

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.

Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

P2888

bmt.2012.218

P304

646-650

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2012.218

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233724423

http://www.w3.org/2001/XMLSchema#string

P698

23165491

http://www.w3.org/2001/XMLSchema#string

Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant.

about

P2860

P2860

Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P698